Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

BACKGROUND. Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor). METHODS. The...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wolpin, Brian M., Ng, Kimmie, Zhu, Andrew X., Abrams, Thomas, Enzinger, Peter C., McCleary, Nadine J., Schrag, Deborah, Kwak, Eunice L., Allen, Jill N., Bhargava, Pankaj, Chan, Jennifer A., Goessling, Wolfram, Blaszkowsky, Lawrence S., Supko, Jeffrey G., Elliot, Meaghan, Sato, Kaori, Regan, Eileen, Meyerhardt, Jeffrey A., Fuchs, Charles S.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639523/
https://ncbi.nlm.nih.gov/pubmed/23580238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0378
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados